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ABSTRACT
SYNTHESIS OF HYBRID INOSITOL GLYCAN ANALOGUES
by Smita Fulzele
Inositol glycans (IGs) are small oligosaccharides exhibiting insulin-like
metabolic activities in insulin-sensitive cells. The signal transduction pathways
activated by IGs in these cells are still under study, but it is known that there is
cross talk between the IG-signaling pathway and the insulin-signaling pathway
downstream of the insulin receptor. Therefore, IGs may have potential for use in
the treatment of type II diabetes mellitus. However, natural IGs are
heterogeneous and difficult to isolate. Hence, synthetic IGs and their analogues
have been chemically synthesized and evaluated for insulin-mimetic properties
by various research groups. Unfortunately, the most biologically active IG
analogues are structurally complex and difficult to synthesize.
The present work reports the progress towards designing and preparing
biologically active IG analogues with short and relatively simple synthetic
pathways. The strategy is to synthesize a small library of hybrid inositol glycan
analogues (HIGAs) where each HIGA consists of an inositol core covalently
tethered to a variety of readily available non-carbohydrate moieties. Synthesis of
one such HIGA (compound 16) was successfully accomplished. Initial results
from mass spectrometric analysis provide evidence of molecular mass of
compound 16.
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CHAPTER 1
INTRODUCTION

1.1 Glycosylphosphatidylinositols
Glycosylphosphatidylinositols (GPIs) are complex glycolipids that are
ubiquitous in eukaryotic cells. GPIs play an important role in anchoring proteins,
polysaccharides and small oligosaccharides to cell membranes.1 Non-proteinlinked or free GPIs that exist in species such as protozoa and mammalian cells
share some similarities with GPI protein anchors. Interestingly, one similarity is
that both free-GPI and GPI anchors share a conserved glycan core.2
GPI anchors synthesized in the endoplasmic reticulum of eukaryotic cells
were first characterized more than two decades ago. The phospholipase
discovered in Bacillus cereus, which hydrolyzes GPIs and is known as
phosphatidylinositol-specific phospholipase C (PI-PLC), was found to release
certain proteins like alkaline phosphatases from the plasma membrane. This
provided evidence of an anchoring system on the plasma membrane. Based on
structural data and compositional studies on purified PI-PLC from different
species likeTrypanosoma brucei, rat Thy-1 and human and bovine erythrocyte
acetylcholinesterase, the existence of GPI anchors was confirmed in 1985. In
1988, the first structure of a GPI anchor was resolved from Trypanosoma brucei
(Figure 1).3 Today hundreds of GPI-anchored proteins are known from human
and a variety of protozoa, fungi, and other eukaryotes.
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Figure 1. Structure of GPI anchor from Trypanosoma brucei.

1.1.1 Structure of GPI anchors
GPI anchors have a complex structure with a highly conserved core
structure. The conserved core structure consists of three parts: a glycan core, a
linker and a tail (Figure 2).4 The GPI-anchored protein links to the core glycan
through an ethanolamine bridge. The core glycan consists of mannose (α1-2)
mannose-(α1-6) mannose (α1-4) glucosamine (α1-6)-myo-inositol. A
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phospholipid tail extends from carbon one of myo-inositol and anchors to the cell
membrane.

O
H 2N

Protein

C

NH
CH2
Ethanolamine

CH2
O
O

P
O

HO
HO

O
OH
O

Man α1−2

OH
O

Man α1−6

O

HO
HO

O
HO
HO

Man α1−4
OH
O
HOH2C
O

O

HO
HO

HO

GlcNα1−6

NH2
O
O

Phosphatidylinositol

OH

O

P

HO
O

O
CH2CHCH2
R 1 R2

Figure 2. General structure of a GPI anchor.

The phospholipid tail and the core glycan structure have variations in
structure imparting heterogeneity to the GPI anchors. Additionally, mannose
residues can have side chain modifications (e.g., galactose, sialic acid).5

3

1.1.2 Role of GPIs
GPIs are suggested to be involved in numerous biological activities.
However, the only confirmed biological function of the GPI anchor is to provide
the protein a stable membrane-anchoring tool. Other biological functions where
GPI anchors could have a putative role include lipid-raft partitioning, cellular
communication, signal transduction, and apical membrane targeting.6 GPI
phospholipids are also thought to be precursors to biologically active inositol
phosphoglycan (IPG) or inositol glycans (IGs). PI-PLC hydrolyzes the
phosphodiester bond of phosphatidylinositol to form 1, 2-diacylglycerol and
glycopeptide-bound (in GPI anchor) or glycan-bound (in free-GPI) inositol-1, 2cyclic-phosphate. Glycosylphosphatidylinositol-specific phospholipase D (GPIPLD) can also hydrolyze GPI anchors. The hydrolysis products of GPI-PLD are
phosphatidic acid and IPG lacking a cyclic phosphate, as shown in Figure 3.2,7
Hydrolysis of GPI phospholipids generates different types of IPGs (also known as
phosphotidylinositol glycan). At least two IPGs, IPG type A and IPG type P, are
known. IPG type A contains myo-inositol and glucosamine, and IPG type P
contains α-pinitol, which is 3-O-methyl D-chiro-inositol and galactosamine along
with additional sugar and phosphate residues. A complete structure of an IPG-P
reported in literature contains a disaccharide of α–pinitol and galactosamine with
Mn2+. It was shown to activate pyruvate dehydrogenase phosphatase.8 The
hydrolysis products are potential insulin second messengers because they
demonstrate insulin-mimetic activities; 9 this issue will be discussed in later
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sections on IPGs. However, the generation of IPG from GPI glycolipids remains
a topic of debate, as the exact source of IPG is yet to be determined.
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Figure 3. Mechanism of hydrolysis of GPI phospholipid by PLC and PLD. INS:
myo-inositol; GlcN: glucosamine; PA: phosphatidic acid; DAG: diacylglycerol
1.2 Inositolphosphoglycans
IPGs were first identified in 1986 from bovine liver treated with insulin.10
A number of in vitro studies established that IPGs exhibit insulin-mimetic
properties. IPGs mimicked insulin’s phosphorylation pattern in freshly isolated
adipocytes.11 Misek and Saltiel in 1992, studied the effects of an IPG generated
by pronase digestion from Trypanosoma brucei membrane glycoprotein on rat
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adipocytes and hepatocytes. It was demonstrated that IPG inhibits lipolysis,
(inhibiting lipid breakdown), glucose 6-phosphatase and fructose-1, 6diphosphatase.12 Further, in an in vivo study, two IPGs in streptozotocin diabetic
rats exhibited insulin-like action by reducing dose-dependent hyperglycemia.13
Such studies indicated that IPGs are potential second messengers of insulin
action and play a role in insulin signaling. This characteristic property of the IPG
can be vital and hence exploited for the treatment of type II diabetes mellitus
where insulin resistance is the cause of the disease.
1.3 Overview of diabetes mellitus
1.3.1 Glucose homeostasis
Glucose, a vital source of energy for cells, is under homeostatic control of
the body which maintains glucose levels within a narrow range of 4–7 mmol/L.
Glucose homeostasis relies on the balance of two hormones, insulin and
glucagon. Both hormones are secreted by islet cells of the pancreas, insulin by
pancreatic β-cells and glucagon by pancreatic α-cells. Insulin and glucagon are
both secreted in response to blood glucose level but are opposite in action.
Insulin decreases blood glucose level while glucagon increases it. Briefly, the
process starts when food is consumed and broken down into fat, protein and
carbohydrates. During the process of digestion, carbohydrates are further
broken down into simple sugars, one of which is glucose. Glucose gets
absorbed in the blood stream and is carried to cells. Sensing increased levels of
glucose in the blood stream, the pancreas produces and releases insulin in the
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blood stream. Insulin binds to the insulin receptor on the cells (fat or muscle
cells), and facilitates glucose uptake by the cells where it is used for energy or
stored in glucogen or fat. Thus, insulin decreases the blood glucose level. When
the level of glucose in the blood drops below the desired level, the pancreas
releases glucagon, which signals the break down of glycogen into glucose, and
its release in the blood stream. In this way, glucose level is maintained between
4-7 mmol/L. However, the inability of the body to maintain the normal range of
blood sugar levels can be reflective of a medical condition. High blood glucose
level is referred to as hyperglycemia, and it characterizes the complex disease,
diabetes mellitus.
1.3.2 Diabetes mellitus
Diabetes mellitus is a chronic endocrine disorder affecting almost 170
million people of all age groups, families and diverse societies worldwide. In the
U.S. alone, 23.6 million (i.e. 7.8% of the population) have diabetes. These
numbers are expected to increase to 48 million by year 2050. The cost of
diabetes care accounts for over 12% of all health care costs, nearly $200 billion
per year which results in a significant burden on the country’s health budget.14
Slow progression of symptoms and the complex nature of the disease makes
early diagnosis difficult. Diabetes is characterized by hyperglycemia, and the two
reasons for the inability of cells to take up glucose are used to describe the two
types of diabetes: type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus
(T2DM). T1DM is characterized by diminished or no insulin production. It was
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previously known as insulin-dependent diabetes mellitus. The pancreas is not
able to produce insulin because the β-cells has been destroyed. Insulin
resistance and impairment of insulin secretion characterize T2DM. It was
previously known as non-insulin dependent diabetes mellitus or adult-onset
diabetes. T2DM is more prevalent than T1DM, accounting for 90% of the total
population diagnosed with diabetes. Other less prevalent forms of diabetes
include gestational diabetes (glucose intolerance during pregnancy), prediabetes and diabetes developed due to pancreatic disease, medications,
surgery or other genetic condition.
T2DM commences as insulin resistance, which is the inability of insulin to
stimulate the target cells to take up glucose. This increased glucose level is
compensated by overproduction of insulin by the pancreatic β-cells. Over a
period of time, β-cell function declines leading to hyperglycemia. Excessive
production of glucose by breakdown of glycogen in the liver, increased insulin
resistance due to obesity and decreased levels of glucagon-like peptide 1 are
also factors that are associated with the disease condition.15 Genetic,
environmental and other lifestyle factors are also thought to play a role. However
the exact causes of T2DM remains unknown.16
Insulin resistance is the major defect in the pathogenesis of T2DM and
insulin resistance is linked to some flaws in the insulin signal transduction.17
Thus, understanding the intracellular insulin signaling transduction pathway may
provide insights into the origin of insulin resistance and pathogenesis of T2DM.
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1.4 Overview of insulin signal transduction
The discovery of the insulin receptor in 1985 led to significant progress in
understanding insulin signal transduction.

Figure 4. Schematic representation of insulin signal transduction. (Reproduced
from Future Medicinal Chemistry (2009), 1(1), 95-118 with permission of Future
Science Ltd).
One of the established and better-understood insulin-signaling pathways
involves phosphorylation on tyrosine residues of the insulin receptor that leads to
a phosphorylation cascade downstream of the insulin receptor (Figure 4).
9

Insulin binds on the α-subunit of the insulin receptor leading to
conformational changes in the β-subunit of the insulin receptor. This
conformational change activates a phosphorylation cascade, and the cytosolic
subunits of the insulin receptor (IR) phosphorylate each other exhibiting
increased kinase activity. This increased kinase activity increases the affinity of
the cytosolic subunits towards other insulin receptor substrate (IRS). The
tyrosine residues of the IRS are phosphorylated upon binding to the IR to which
the regulatory domain (p85) of PI3 kinase binds. Binding of p85 leads to the
generation of lipid phosphatidylinositol-3, 4, 5-triphosphate by phosphorylation of
phosphatidylinositol-4, 5-diphosphate. This increases the concentration of lipid
phosphatidylinositol-3, 4, 5-triphosphate and leads to a cascade of
phosphorylation reactions of various proteins. The concentration of PIP3 is
further controlled by two enzymes, Ship 2 and Phen.18 Phosphoinositidedependent kinase 1 and a second putative kinase named phosphoinositidedependent kinase 2, binds and activates protein kinase B (PKB). Activated PKB
is suggested to be a key element in insulin’s metabolic action and is believed to
be involved in almost all of insulin’s actions like glycogen synthesis, glucose
transport and protein synthesis in muscle cells and adipocytes.19 Glycogen
synthesis is initialized by phosphorylation of glycogen synthase kinase by PKB
which deactivates glycogen synthase kinase but leads to activation of glycogen
synthase, ultimately leading to glycogen synthesis. Deactivation of glycogen
synthase kinase results in a reduced level of phophorylation of adenosine tri
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phosphate citrate lyase, but phosphorylation by PKB at a different site on the
adenosine triphosphate citrate lyase increases the activity of adenosine
triphosphate citrate lyase. Further, adenosine triphosphate citrate lyase
catalyzes conversion of citrate to acetyl co-enzyme A that is utilized in lipid
synthesis. Glucose uptake is another metabolic action of insulin. There are two
different pathways through which groups of glucose transporter (GLUT) proteins
facilitate glucose uptake by cells, although they are yet to be characterized. One
pathway involves activation of GLUT4 vesicles directly by PKB or activation
through an atypical protein kinase C (PKC), while the second commences
directly below the IR. Activation of IR, post insulin binding, leads to
phosphorylation of Cb1 and an adaptor protein, Cb1 associated proteins, which
exist as a complex. The phosphorylated complex then interacts with Crk II,
which is associated with a guanine nucleotide exchange factor of the Rho-family.
TC10, a member of guanosine triphosphate-binding protein family, is activated by
guanine nucleotide exchange factor, and this leads to GLUT4 translocation via
adaptor proteins by a mechanism that is not fully elucidated.20 In addition to
glucose storage, insulin mediates the breakdown of lipids (lipolysis) and inhibits
the production of glucose in the liver (gluconeogenesis). A phosphodiesterase
3B is activated by an unknown mechanism that reduces the cyclic adenosine
monophosphate levels by hydrolysis. Reduced cyclic adenosine monophosphate
levels reduce protein kinase A (PKA) activity, which in turn fails to phosphorylate
hormone sensitive lipase. The inactive (unphosphorylated) form of hormone
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sensitive lipase thus reduces lipolysis. Inactive PKA also fails to phosphorylate
fructose 2, 6-bisphosphatase and prevents conversion of fructose 2, 6bisphosphate to fructose-6-phosphatase. Fructose 2, 6-bisphosphatase is
inhibited by increased fructose 2, 6-bisphosphate secretions thus resulting in
gluconeogenesis.
1.4.1 Defects in insulin signal transduction
Identifying defects in the intracellular signaling cascade can be
challenging as the defects can be at several levels. Defects in the IR have been
implicated in insulin resistance. Mutations of the IR and some transcription
factors like peroxisome proliferator-activated receptor-γ have been reported.21
The location of some IR in caveolae is noteworthy. Caveolae microdomains and
caveolin-1 are thought to be regulatory components in insulin signaling.
Caveolae are invaginations found in the plasma membrane of different cell-types
like adipocytes, myocytes and endothelial cells. They are rich in cholesterol and
sphingolipids, just like lipid rafts, making them detergent insoluble and thus
representing a class of detergent/carbonate-insoluble glycolipid (DIG) enriched
microdomains. Caveolin-1, belonging to the caveolin gene family, is a
cholesterol-binding integral membrane protein and a structural component of
caveolae. Studies on rat adipocytes using immunogold electron microscopy
established that the IR has high caveolae content. These studies indicated that
GLUT4 translocation occurred in caveolin-rich membrane fractions. These
observations were indicative of interactions between caveolae and caveolin-1
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with IR, but their exact role in insulin signal transduction remains to be
determined. However, mutations in caveolin-1 have been linked with severe
insulin-resistance.22 Internalization of the insulin-insulin receptor complex into
endosomes and degradation of insulin by insulin degrading enzymes are also
suggested to terminate the insulin-signaling cascade.23 On the other hand,
internalization of the receptor complex is thought to be favorable such that the
receptor complex can access the downstream effectors and continue insulin
signaling. However, the effects of receptor complex internalization are not fully
understood and remain a topic of active investigation.24 Components like proteintyrosine-phosphatases namely protein-tyrosine-phosphatases-1B that interacts
directly with the IR has been reported to be involved in insulin resistance. The
absence of this phosphatase in protein-tyrosine-phosphatases-1B knockout mice
resulted in an increased sensitivity to insulin in skeletal muscles due to increased
phosphorylation of IR and IRS-1.25 Some studies have indicated that release of
free fatty acids and adipocytokines, like tumor necrosis factor-α in skeletal
muscle, is linked with dysregulation of the insulin receptor resulting in insulin
resistance. However not all researchers concur on the role of tumor necrosis
factor-α in insulin resistance, and hence the topic is contentious.17 Another
kinase PKC, similar to PKB, is activated by insulin. PKC is thought to induce
phosphorylation on residue Ser612 of IRS-1, thus inhibiting insulin signaling and
resulting in insulin resistance.26 Another study has linked increased
phosphorylation of Ser307 on IRS-1 with tumor necrosis factor-α stimulation which
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results in downregulation of IRS-1.27 Yet another study associated increased
Ser307 phosphorylation with insulin resistance, corroborating the role of Ser307 on
IRS-1 in insulin resistance.28 Identifying such defects in the intracellular signaling
cascade is challenging but would provide an in-depth understanding of causes of
T2DM and potential targets for designing new and improved drugs for the
treatment of T2DM.
1.4.2 Available treatment options
Acute complications of diabetes include hypoglycemia and ketoacidosis,
while chronic conditions include diabetic nephropathy, neuropathy resulting in
amputations, coronary artery disease, stroke, hypertension and hyperlipidemia.
Stringent lifestyle modifications, including diet and exercise, are key measures in
management of diabetes but are not enough for effective control of the disease,
and therefore use of anti-diabetic drugs becomes indispensable for prevention,
management and treatment of patients.
The drug classes currently approved for treatment of T2DM include
insulin, sulfonylureas, thiazolidinediones, glucagon like peptide-1 mimetics,
amylin mimetics and dipeptidyl peptidase-IV inhibitors. Sulfonylurea derivatives
are insulin secretagogues, which exert their effect of reducing blood glucose
levels by stimulating insulin release from pancreatic beta cells.
Thiazolidinediones are insulin-sensitizing, and they act by binding to a nuclear
regulatory protein, peroxisome proliferator-activated receptor-γ, which is involved
transcription of genes controlling glucose and fat metabolism.29 Dipeptidyl
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peptidase-IV inhibitors, as the name indicates, exert their action by inhibiting
degradation of dipeptidyl peptidase-IV. This increases the level of incretin,
glucagon like peptide-1 in the blood and improves glycemic control. Dipeptidyl
peptidase-IV is also suggested to improve β-cell mass due to its mechanism of
action.30 Glucagon like peptide-1analogues and agonists are incretins that
respond to increased glucose levels by secretion of more insulin. Incretins also
inhibit glucagon secretion and thus maintain normal blood glucose levels.31
Combination therapy and alternative medicinal sources, like plants, fungi and
complex microbial secondary metabolites, have been explored as potential
therapeutic agents for T2DM. There are a number of new classes of therapeutic
agents, but none are optimal and none alone (other than insulin or insulin
analogues) can achieve sustained satisfactory results. These agents are also
associated with side effects and complications. On the other hand, the ability of
IPGs to by-pass the defects of IR in the insulin signaling pathway that causes
insulin resistance qualifies IPGs as potential anti-diabetic drugs. How would
these IPGs then modulate the insulin-signaling pathway? Is there really a
second messenger pathway that exists? If yes, at what stage do they converge?
There have been numerous studies to seek answers to these questions as
discussed below.
1.5 IPGs: second messengers of insulin signaling
Several reports in the literature propose an alternate pathway to the
phosphorylation pathway.32-34 In the second messenger pathway, the second
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messengers or insulin mediators exhibit potential to intervene insulin’s effect in
parallel to the phosphorylation cascade pathway. Data indicating the existence
of an alternate pathway was first reported by Larner and coworkers.35 However,
not much information was available on the identity of the second messengers
until Saltiel and co-workers in 1986 reported purification methods for structural
characterization of some second messengers. It was demonstrated that insulin
stimulated hydrolysis of GPI molecules by PLC yields two mediators, IPG and
diacylglycerol that act as the second messengers.36 Some studies also indicated
a possible role for the guanine nucleotide-binding protein known as the G-protein
in production of the second messenger.33 However, a number of questions
remain unanswered. Controversy continues pertaining to questions about the
GPI target molecule and its hydrolysis. Whether the GPI precursor is a GPIanchored protein or a free-GPI is not clear. Furthermore, the cleavage of the
GPI molecule can occur by either the PLC or possibly by PLD. If GPI hydrolysis
occurs by PLC, is it due to G-protein stimulation or activation through tyrosine
phophorylation of IR? Likewise, the structure and mechanism of action of Gproteins in relation to insulin remain to be established. Nevertheless, numerous
in vitro and in vivo studies on the insulin mediator, IPG, from various sources
indicated that IPGs are insulin-mimetic.
Although the second messenger pathway remains less understood, a lot
of effort has been directed in understanding the mode of action of second
messengers as related to the effects of insulin. At least two pathways are
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proposed. One pathway hypothesizes that insulin binding activates PLC and that
GPI hydrolysis occurs releasing IPG and diacylglycerol at the outer leaflet of the
cell membranes. IPG enters the cells via an adenosine triphosphate-dependent
IG transporter but bypasses the IR, exerting insulin-like effects by modulating
proteins involved in the signaling pathway.2 Another study showed that both
natural and synthetic IGs in a cell-free assay could modulate pyruvate
dehydrogenase phosphatase activity suggesting an intracellular role.37 On the
contrary, IGs also appear to stimulate cells without entering them, as
demonstrated by the study on a fluorescent-labeled synthetic IG analogue. This
IG analogue was found to stimulate lipogenesis in rat adipocytes without
internalization in cells.38 The second proposed pathway could help explain the
above observation for the fluorescent-labeled synthetic IG analogue. This
pathway, proposed by Muller and coworkers,39 attributes IG’s mode of action to
the dynamics of plasma membrane microdomains. DIG microdomains are
suggested to be heterogeneous, consisting of high cholesterol (hcDIGs) and low
cholesterol (lcDIGs) regions. GPI-anchored proteins and the non-receptor
tyrosine kinase (NRTK), pp59Lyn are found to be located in hcDIG enriched with
caveolin and lipid-modified signaling proteins. Cytoplasmic signaling proteins
with dually acylated long chain fatty acids interact with caveolin in hcDIG. A
caveolin scaffolding domain has been shown to interact with high specificity with
a caveolin-binding domain on signaling proteins.
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Figure 5. Schematic representation of IPGs and insulin signaling. (Reproduced
from Future Medicinal Chemistry (2009), 1(1), 95-118 with permission of Future
Science Ltd).
This type of interaction and another protein-protein interaction between
flotillin and sorbin homology domain is thought to be important for recruitment of
signaling proteins to DIG. A putative IG receptor for endogenous ligands such as
GPI proteins/lipids has been reported. The IG receptor is a 115 kD
polypeptide.40 The proposed pathway is summarized in Figure 5.41 Each step
described below corresponds to the numbers indicated in Figure 5. (1) Insulin
stimulates GPI-PLC. (2) This enzyme then lipolytically cleaves GPI-anchored
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proteins (or free GPIs) on the outer side of the cell membrane. (3) The proteinIG conjugate (or IGs) competes with the GPI for the receptor, thus (4)
dissociating the GPI-anchored proteins from the receptor, which translocate to an
lcDIG microdomain. (5) Acylated NRTKs such as pp59Lyn on the inner leaflet are
redistributed between hcDIG and lcDIG. This could be a repercussion of the
changed lipid content brought by the translocation of GPI-anchored proteins to
the hcDIG. (6) Kinase pp59Lyn activates pp125Fak which (7) recruits IRS protein
for (8) phosphorylation by pp59Lyn at sites that are recognized by PI3K. This
activates the phosphorylation cascade and serves as a point of covergence
between the IG signaling pathway and the classical phosphorylation pathway.
1.6 Synthetic IPGs
IPGs, with their promising potential as therapeutic agents for T2DM
treatment, have motivated various research groups to isolate IPGs from natural
sources. Efforts are also being made to elucidate their structural composition
and perhaps understand the mode of action. This is a daunting task as IPGs are
heterogeneous. For example, IPG from rat liver and IPG from hepatoma cells
contain chiro-inositol, while IPGs from rat liver, rat adipocytes, and BC3H-1
myocytes contain myo-inositol.10-11, 42-43 In addition, the low amounts of isolated
IGs from natural sources has contributed to the fact that the exact structure of IG
has not been elucidated. A plethora of studies were therefore directed towards
identifying the structural composition of IGs. The aim was to overcome the
limitation of isolation of IPGs and alternatively rely on chemical synthesis to
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produce IPGs of defined structure. The first definitive reports on GPI and IG
structure were reported by Larner’s43 and Mato’s group.11 The structural IG
components identified were a terminal inositol group, either myo-inositol or chiroinositol,11 an aminosugar glucosamine or galactosamine, and mannose residues
with one or more phosphate groups. Based on metabolic labeling and
degradation studies, it was also realized that the approximate molecular weight
of 1400 Da for IGs made them closely related in size to the GPI membrane
anchors.10 GPI structure was explored as a model for designing IGs. d’Alarcao
and co-workers44 synthesized the first synthetic IG in 1992. It was an IPG-A
pseudodissaccharide, compound 1, which was reported to stimulate lipogenesis
in rat adipocytes (Figure 6).
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Figure 6. Structure of first synthetic IPG, 1.

Three other compounds, synthesized at the same time, were shown to
exhibit no insulin-mimetic activity. Based on these observations, the authors
concluded that an amino-sugar in conjunction with myo-inositol-1, 2-cyclic
phosphate was the minimum structural requirement for an IG to exhibit insulinmimetic activity. This study pioneered the chemical synthesis of IGs, and
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numerous research groups have now synthesized and evaluated IGs for insulinmimetic activity.
A few years after the d’Alarcao paper 44, Muller and coworkers reported
the synthesis and evaluation of 46 different IG analogues.45 The most potent
IPG, 41, was a pseudohexasaccharide containing a myo-inositol-1, 2-cyclic
phosphate, glucosamine, and four mannose residues with sulfate groups on two
mannose residues (Figure 7).
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Figure 7. Structure of potent IPG, 41.

The authors demonstrated that some synthetic IGs, in low micromolar
concentration, could elicit insulin-mimetic activity up to 90% compared to insulin.
The study further established that a minimum of one anionic group distal to the
inositol core is required for high activity. Additionally, it was shown that the
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anomeric configuration between glucosamine and the inositol core was
insignificant, as compounds containing either α or β linkages were equally active.
Although, the activity of compound 41 reported by Muller’s group 45 was striking,
the synthetic pathway was lengthy. A study by Chakraborty and d'Alarcao 46
reported a simpler, synthetic pathway to biologically active IG compounds. Two
mannose residues in pseudotetrasaccharides 3 and 4 (Figure 8), instead of four
in compound 41, retained insulin-mimetic activity and stimulated lipogenesis in
adipocytes.46
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Figure 8. Structures of IPG 3α,β and 4α,β

The same group further reported synthesis of the non-hydrolyzable,
palmitoylated IG, IG-1.47 This synthetic IG showed the insulin-mimetic property
of inhibiting lipogenesis with a reported activity of 24% MIR (maximum insulin
response) with EC50 (effective concentration producing 50% cell kill) of 14 µM.
This compound was also reported to have cytotoxic effects on some human
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cancer cell lines. Additionally, it was realized that IG-1 is highly selective in
killing cancer cells. Based on these observations and comparing the activity of
IG-1 with known anti-cancer agents like resveratrol and butyrate which induce
apoptosis in cancer cells, it was hypothesized that IG-1 has anti-cancer
properties and acts by reversing the Warburg effect, causing apoptosis in cancer
cells. However, the presence of an ester linkage, which undergoes hydrolysis
under physiological conditions, limited the use of IG-1 as an anti-cancer agent.47
To overcome this limitation, the same group 48 recently reported the synthesis of
an ether analogue of IG-1, a non-hydrolyzable, palmitylated IG. Preliminary data
on this IG suggest that it is considerably more stable than IG-1 and exhibits
similar biological activity.48
The potential of IPGs as second messengers cannot be stressed enough.
The above two studies support the development of IPGs as a potential anticancer agent. Yet another study has implicated IPGs in transmembrane
signaling in T lymphocytes.49 Thus, it is evident that IPGs can have wider roles in
signal transduction. However, the exact structure of IG, its mechanism of action,
and its role in signal transduction need to be fully elucidated. A major challenge
in doing so is the fact that the most active synthetic IPGs are also the most
complex and, thus, involve lengthy synthetic schemes for preparation that make
it difficult to obtain sufficient quantities for biological evaluations. Smaller and
simpler IPGs showed a low insulin-mimetic activity as compared to active IPGs
like compound 41. d’Alarcao and coworkers reported an important and
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interesting observation on a relatively simple fluorescent IPG derivative. In an
effort to study IPG’s mechanism of action, the researchers modified the first
synthetic IPG from 1992, compound 1, to make the fluorescent-labeled IPG, 17
(Figure 9).
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Figure 9. Structure of fluorescent-labeled IPG, 17.

Compound 17 was prepared by coupling the 6-thiol-analogue of
compound 1 with a commercially available iodoacetamide derivative of Lucifer
yellow. The authors expected compound 17 to be weakly active but to serve as
a good mechanistic probe. However to their delight, compound 17 was more
active than compound 3. It was found to stimulate lipogenesis with maximal
activity of 47% relative to that of the maximal insulin response (MIR, defined as
the stimulation by 5 nM insulin) and to have an EC50 of 12 µM.38 The authors
attributed the increased activity of compound 17 to the correct positioning of ionic
groups on the IG and the Lucifer yellow fluorescent probe, a possible key
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structural feature for the IGs to be active. Thus, it was clearly demonstrated that
IG simpler analogues possessing the correct array of ionic groups even on a
non-carbohydrate moiety like the Lucifer yellow chromophore could be
biologically active. This study serves as a foundation for the proposed research.

25

CHAPTER 2
RESEARCH GOAL AND SYNTHETIC PLAN

2.1 Research goal
Synthetic IGs show great potential as therapeutic agents in the treatment
of T2DM and cancer. However, most therapeutically active IGs are large
complex compounds with lengthy and difficult synthetic pathways, which limit
their therapeutic utility.
The primary goal of the proposed research is to synthesize a series of
hybrid inositol glycan analogues (HIGAs) consisting of an inositol precursor
coupled to a variety of non-carbohydrate moieties. The inositol core could be
synthesized to accommodate cyclic phosphate and/or palmitate to form in
analogues that resemble the biologically active IG structure. Compound 17, a
thiol analogue of compound 1 coupled to a non-carbohydrate moiety, is
considered as the lead compound. As discussed in section 1.6 of chapter 1, the
correct positioning of ionic groups on 17 is presumed to be the reason for the
observed high activity. Based on the results from the studies conducted on
compound 17, it is hypothesized that some of the newly synthesized HIGAs
could be biologically active.
The proposed shorter synthesis pathway of HIGAs will overcome the
drawback of lengthy and complex synthesis of the current biologically active IGs.
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The synthesized HIGAs will be evaluated for insulin-like activities such as
stimulation of glucose transport, glycogen synthesis and lipogenesis.
2. 2 Synthetic strategy
Two strategies are proposed for the design and preparation of HIGAs.
2.2.1 Strategy 1
The first strategy is to use the ‘Traceless Staudinger Ligation’ method for
synthesizing HIGAs. Traceless Staudinger ligation is a modification of the wellknown Staudinger reduction reaction. The Staudinger ligation enables the
formation of an amide bond between a phosphinoester (or phosphinothioester)
and an azide group.50 The by-product of the reaction, phosphine oxide, is
expelled and does not form a part of the final product (contrary to the Staudinger
reduction) and, hence, is known as a traceless method. An advantage of the
traceless Staudinger ligation lies with the involvement of specific functional
groups in the ligation process, the azide and the phosphine derivative. The
mechanism of traceless Staudinger ligation allows a wide variety of modifications
especially in the phosphine functional group. Additionally, the traceless
Staudinger ligation reaction is highly chemoselective and can be carried out at
room temperature in an aqueous environment. Furthermore, it is compatible with
diverse functional groups, and therefore, is widely used in the field of organic
synthesis and chemical biology. It is also used as a powerful tool in peptide
ligations.51
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The retro synthetic analysis utilizing this coupling strategy is shown in
Scheme 1.52-54

Scheme 1. Synthesis of HIGA by traceless Staudinger ligation. 52-54
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Compound 28 could be obtained by tethering the non-carbohydrate
moiety, 27 to thiol containing 26. Compound 26 could be obtained by
deprotection of 25, which in turn could be obtained by coupling 15 with 24 by the
traceless Staudinger ligation method. Scheme 2 shows the retrosynthetic
analysis for preparation of 24.55,56
Compound 24, a phosphinothioester, could be obtained from 23 by
deprotection, which, in turn, could be obtained by esterification of 20 and 22.
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Compound 22 can be obtained by fluorenylmethoxy carbonyl chloride (fmoc)
protection of the thiol and amino groups of commercially available cysteine.
Compound 20 could be obtained in 4 steps from commercially available
chloromethylphosphonic acid dichloride.56

Scheme 2. Synthesis of phosphinothioester.55,56
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Cysteine was a reagent of choice for synthesizing phosphinothioester, 24,
for two reasons. Firstly, based on the data from several labs on IGs, it was
observed that cyclic phosphate and a neighboring amino group are
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characteristics of the most active IGs.44, 45, 57 The amino group of cysteine would
thus fulfill the requirement of a much-needed amino group as a structural
component of HIGA. Secondly, the thiol group could serve as a linker for the
non-carbohydrate appendages. Fmoc is a widely used protecting group in
peptide synthesis and in organic synthesis for protection of amines. The
advantages of the fmoc protecting group are its easy cleavage under mild basic
conditions and its stability under acidic conditions.
Scheme 3 shows the retrosynthetic analysis for preparation of 15. 55, 58-63
Compound 15 could be synthesized in 14 steps from commercially available Dxylose. D-xylose was chosen as the starting material due to its availability and
cost. The overall yield of this set of reactions is about 15-20%, but the
advantage is that the reactions can be executed on a larger production scale.

Scheme 3. Synthesis of 15.55, 58-63

OBn
BnO

OBn
O

O
P

BnO

O
N3

15

O

5
Steps

BnO

3
Steps

BnO

OBn

OBn
OH

OH

BnO

BnO

OTIPS

10b

HO
Steps HO

BnO

BnO

O

6

OH

OH

7a

7b

OH

OH

1

Based on strategy 1, the goal was to accomplish the parallel syntheses of
15, 20 and 22. Synthesis of 7a and 7b from 1, towards the synthesis of 15, was
successfully achieved. Despite certain difficulties compound 22 was successfully
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synthesized. Compound 17 and 18 were successfully synthesized from starting
material, 16, towards the synthesis of 20. However, no success was achieved in
synthesizing compound 19.
While strategy 1 involved a novel synthetic route to 28, it was lengthy, and
a need for a shorter synthetic scheme was realized. Based on a further literature
search an alternative, shorter synthetic scheme was designed.
2.2.2 Strategy 2
Strategy 2 was designed for a shorter synthetic route to HIGAs. The
coupling strategy explored was the Huisgen cycloaddition reaction. With this
strategy the target HIGA could be obtained in 15 steps versus 26 steps as in
strategy 1.
The Huisgen cycloaddition reaction is a powerful coupling strategy that is
very specific and is biocompatible with a variety of reactants.64 It is a 1, 3-dipolarcycloaddition reaction, which is categorized as a “click” reaction. There are
variants of the 1,3-dipolar Huisgen cycloaddition, and the one employed for this
strategy was the copper catalyzed azide-alkyne Huisgen cycloaddition reaction
that generates a 1,2,3-triazole system. The copper catalyzed azide-alkyne
Huisgen cycloaddition reaction requires simple reaction conditions, and starting
materials that are readily available. These reasons led to the selection of this
coupling method for strategy 2.
A retrosynthetic analysis for preparation of HIGA is shown in Scheme
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4a and 4b.52,53,65-70 Compound 16 could be obtained by coupling 15 (noncarbohydrate moiety) with 14. Compound 14 could be obtained by global
deprotection of 13. Benzyl ethers are easy to remove and, hence, were
employed as protective groups for alcohol and thiol groups in this synthesis.
Compound 13 could be obtained by installing a cyclic phosphate on C1 and C2
of 12. Compound 12 can be obtained by a “click” reaction between 11 and 10b.

Scheme 4a. Synthesis of HIGA.52,53,65-67
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Compound 11 could be synthesized in one step from commercially
available α-toluene thiol and propargyl bromide. Compound 10b can be obtained
after its separation from a mixture containing both undesired and desired diols,
10a and 10b respectively (shown in figure 12). Compound 10a and 10b could be
obtained by dihydroxylation of 9 using catalytic amount of osmium tetroxide and
N-methylmorpholine N-oxide. Although osmium tetroxide is highly toxic, volatile
and expensive, it is one of the most efficient reagents for double bond
dihydroxylation to give the corresponding vicinal diols.71 N-methylmorpholine Noxide is used as a co-oxidant to regenerate the catalyst, osmium tetroxide.
Compound 9 could be obtained from 8b by mesylation followed by nucleophilic
substitution of the resulting mesylate with sodium azide (Scheme 4a).
Compound 8b could be obtained by resolving the diastereomeric mixture of 8a
and 8b by flash chromatography. A Ring closing metathesis reaction on the
mixture of 7a and 7b by using a first generation Grubbs ruthenium catalyst could
produce a mixture of 8a and 8b. The first-generation Grubbs ruthenium catalyst
has the advantage of commercial availability and stability, making handling of the
catalyst easy. Compound 7a and 7b could be obtained in 6 steps from 1
(Scheme 4b). These reactions are well established by Prof. d’Alarcao’s group.62
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Scheme 4b. Synthesis of 10b from 7a and 7b. 68-70

OBn

OBn

OBn
BnO

OH

BnO

BnO

BnO

OH

BnO

BnO

OBn

OBn
BnO

BnO

BnO

BnO

N3

N3

OH

OH

OH

10b

9

8b

7a

7b

OBn

OBn
BnO

BnO

BnO

BnO

6 steps

OH

OH

7a

7b

34

O

HO
HO

OH

1

OH

CHAPTER 3
RESULTS AND DISCUSSION
3.1 Synthesis of fmoc-protected cysteine, 22
Synthesis of 22 was attempted based on a literature procedure.55
Cysteine hydrochloride was treated with fmoc chloride, and thin layer
chromatography (TLC) indicated the complete disappearance of the starting
materials. However, no product could be isolated. Neutralizing cysteine
hydrochloride and raising the pH to 7 with 2 N sodium hydroxide before addition
of fmoc chloride to the reaction mixture proved crucial, and compound 22 was
obtained as a white foam.
3.2 Attempted synthesis of phosphinothiol, 20
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Figure 10. Synthesis of phosphinothiol, 20.56
Synthesis of phosphinothiol was initiated by synthesizing compound 17
from the starting material chloromethylphosphonic acid dichloride, 16, following a
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literature procedure as shown in Figure 10.56 Compound 18 was synthesized
from compound 17. A charcoal treatment for removal of inorganic impurities was
reported in the literature, however a low yield of 13% was observed after the
charcoal treatment. An improved yield of 48% was obtained after omission of the
charcoal treatment step. An extraction process using aqueous sodium
bicarbonate removed traces of acetic acid in the product. Synthesis of
compound 19 from compound 18 was attempted twice, but no product was
obtained. Trichlorosilane, a reagent required for the reaction, has a low boiling
point of 31.8 °C and hence was difficult to be retained inside the reaction vessel.
Attempts were then made to conduct the reaction in a completely sealed system
(a pressurized vessel, a stainless steel bomb) and minimize the loss of
trichlorosilane. In spite of all efforts, no product was obtained.
3.3 Synthesis of benzyl propargyl sulfide, 11
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Figure 11. Synthesis of benzyl propargyl sulfide 11.66

Compound 11 was obtained by propargylation of commercially available
α-toluene thiol (A) with propargyl bromide (B). Product 11 was obtained as
yellow oil with a good yield of 83%.
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3.4 Synthesis of monosaccharide unit, 10a/10b
Compound 10b was obtained in nine steps from D-xylose 1. Compound 2
was obtained from 1 by the Fischer glycosylation reaction, an established
reaction that has been well accomplished in the laboratory. Continued work with
the Fischer glycosylation reaction in our laboratory revealed that yields of the
reaction could be improved by varying the conditions of the reaction. Increasing
the reaction time from 6 to 48h resulted in the increased formation of the
pyranose form of the sugar and less of the furanose form of the sugar, as
monitored by proton nuclear magnetic resonance (NMR). Benzylation of 2 gave
the differentially protected compound 3. Although the reaction was
straightforward, certain difficulties were encountered. The dimsyl anion obtained
from dimethyl sulfoxide and sodium hydride was partially soluble in the reaction
mixture and, hence, had a tendency to form a solid that hampered the stirring
process. The problem was overcome by use of a mechanical stirrer that ensured
continuous mixing. Flash column chromatography was used to purify compound
3, which was obtained in good yield. The next step was hydrolysis of the
methoxy group at the anomeric position of 3 under acidic conditions. The
reaction mixture was refluxed for 12h and filtered. The precipitate was collected
by fractionation and crystallized from hexane-ether. Crystallization of 4 from
hexane-ether as a solvent system proved to be a little complicated, and some
amount of product was lost in the process. Recrystallization of 4 was attempted
from methanol with the aim of improving the yield, and it was successfully
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accomplished. A Wittig reaction was done on compound 4 to convert the
hemiacetal to an alkene. The requirement of absolute anhydrous reaction
conditions was achieved by thoroughly drying reagents utilized in the reaction.
Triphenyl phosphonium salt was dried using a drying pistol for at least 24h.
Compound 4, the starting material for the reaction, was azeotroped 2-3 times
from toluene to get rid of any trace of water. Only freshly distilled tetrahydrofuran
was used in the reaction. Although extensive care was taken to retain anhydrous
conditions for the reaction, the yield of the reaction, post purification, was only
35%. The amount of crude product obtained was more than the expected
theoretical yield. This led us to consider that the loss of product could be
occurring during the purification process. Instead of running flash
chromatography for a longer period of time, purification of the crude was done by
quickly passing the crude through a silica plug to minimize the contact of the
crude with silica. This method of purification resulted in an improved yield of
55% of compound 5. Swern oxidation on compound 5 oxidized the alcohol on C
5 to an aldehyde compound 6. The reaction was clean, and no purification was
required. Compound 6 was then subjected to the Grignard reaction to give a
mixture of isomers 7a and 7b. The use of different reaction conditions can vary
the ratio of isomers 7a and 7b. Luchetti and co-workers in 2008 reported
extensive work on optimizing these reaction conditions. According to the study,
use of an additive, magnesium bromide ethyl etherate, in the Grignard reaction
generated a higher ratio of isomer 7b. This was attributed to the chelating ability
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of the additive.68 The effect of solvent on the ratio of 7a and 7b was also
noteworthy and, with the aim of obtaining a higher ratio of 7b, the ratio of
tetrahydrofuran to dichloromethane used was 2:1 yielding a 2:1 ratio of 7a to 7b.
The next step was ring-closing metathesis (RCM) on 7a and 7b. RCM is an
intermolecular olefin metathesis that yields a cycloalkene. The first generation
Grubbs catalyst was used for RCM to yield conduritols 8a and 8b. Purification by
flash chromatography yielded the desired conduritol, 8b. The next step was
displacement of a hydroxyl group on C6 of 8b by sodium azide to yield 9, as
shown in Figure 12.
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Figure 12. Synthesis of 10a/10b from 8b.

The aim was to synthesize 9 via mesylation followed by displacement of
the resulting mesylate by sodium azide following a literature procedure.69, 70
Accordingly, mesyl chloride was used as a source of the mesyl group, and an
azido-alkene derivative was obtained as the product. Dihydroxylation of the
resulting azido-alkene derivative was the next step. A mixture of two isomers
(diols) was expected as the dihydroxylation product because of the alkene in 9,
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which is flanked by a bulky benzyloxy group on C3 trans to the azide group on
C6. However, formation of only one isomer indicated some flaw during the azide
displacement reaction. This problem was investigated by characterizing the
intermediate mesylate product. Mass analysis revealed a mass corresponding to
8b with a chloride group attached rather than a mesyl group. Based on these
observations, it was hypothesized that the following sequence of steps occurred
during the course of the reaction (Figure 13).
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Figure 13. Synthesis of 8e from 8b.

Compound 8b underwent mesylation to give 8c. The reaction mixture at
this stage had chloride anions (from mesyl chloride) that acted as a nucleophile,
displacing the resulting mesylate to yield 8d. A double displacement with sodium
azide yielded 8e, however with the opposite stereochemistry than the desired
due to an additional SN2 substitution by chloride anion. To circumvent this
problem, mesyl anhydride was used as a mesylating agent, and 8b successfully
yielded compound 9 in the desired stereochemistry. Compound 9 was further
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treated with osmium tetroxide in acetone-water (9:1) to yield a mixture of cisdihydroxylated diols, 10a and 10b, with two OH groups ‘down’ and ‘up’,
respectively. Preparative TLC yielded 10b followed by 10a in a 3:1 ratio.
3.5 Identification and characterization of diols 10a and 10b
The next task was to determine which isomer from the mixture of cisdihydroxylated diols had two OH groups ‘up’ and which isomer had two OH
groups ‘down’. Since NMR spectra were ambiguous for characterization, each
isomer was subjected to a deprotection reaction. Comparing the NMR spectrum
of the resulting deprotected products to that of previously reported products,72, 73
the identities of diols 10a and 10b were determined.
3.6 Synthesis of 12 by click reaction of 10b with 11
Following a literature procedure, a copper catalyzed Huisgen cycloaddition
(click reaction) was done to afford crude 12.67 The reaction was quick and
efficient, and disappearance of starting material on the TLC plates could be seen
in less than 10 minutes. Visualization of the product on the TLC plates, however,
proved tricky, as the product did not stain with p-anisaldehyde stain. HanesIsherwood stain and iodine were also tried, but neither proved efficient for
visualization of the product. Thus, TLC plates were not stained, and ultraviolet
illumination was chosen as the method of visualization. High-resolution mass
spectrometric analysis and a proton NMR spectrum of the crude, proved its
molecular mass to be 12.

41

3.7 Synthesis of compound 16 from 12
The series of reactions to obtain 16 from 12 started by cyclic
phosphorylation of 12 with methyl dichlorophosphate in pyridine following a
known literature procedure.65 Global deprotection of the phosphorylated product,
13, by dissolving metal reduction using an established procedure,53 yielded
compound 14 which was kept under argon atmosphere. The final task was
coupling of 14 with 5-(amino)-naphthalene-1-sulfonic acid (1, 5-IAEDAN), 15.
1, 5-IAEDAN is an organic fluorescent molecule and, hence, widely used as a
marker in fluorescence microscopy. The advantage of using this reagent is that it
has a high solubility in water above pH 4. Tris-HCl buffer (pH 7.5) was used as a
solvent, and compound 14 was added to it followed by the fluorescent dye, 15.
The reaction mixture was protected from light by wrapping with an aluminum foil,
as fluorescence of 15 is dependent on the environment and could be sensitive to
light. The reaction was carried at under argon atmosphere to prevent air
oxidation of the thiol group (present in 14) to form disulfide bonds. Dithiothreitol
or tris-(2-carboxyethyl) phosphine are reagents used to reduce disulfide bonds.
However, earlier studies have reported low yields for coupling reactions when or
tris-(2-carboxyethyl) phosphine was used for reducing disulfide bonds. The
reason for this observation was attributed to the nucleophilic nature of or tris-(2carboxyethyl) phosphine competing for the iodoacetamide.38 Based on this
observation, no disulfide reducing agent was utilized for this coupling reaction.
The reaction mixture was stirred for 2h and fluorescent-labeled HIGA, 16, was
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obtained. High performance liquid chromatography (HPLC) analysis was done to
characterize compound 16. Initial results from HPLC and high resolution mass
spectrometry analysis showed m/z ratio of 322.0865 (versus the calculated mass
of 322.0443), confirming the molecular mass for dianionic compound 16. Further
structure elucidation of 16 would be done by 1H NMR analysis.
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Figure 14. Synthesis of 16 from 12.

43

N

O

CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
The design objective for synthesizing HIGAs was to position ionic groups
in approximate homology to the partially known IG pharmacophore. The
challenge was to accomplish this task in a short and relatively simple synthetic
pathway. The strategy used for this purpose was synthesizing the HIGA to
consist of an inositol core covalently tethered to a variety of readily available noncarbohydrate moieties. Synthesis of one such HIGA (compound 16) was
successfully accomplished. Initial results of mass spectrometric analysis provide
evidence for the structure of compound 16. Further studies for structural
elucidation of compound 16 are underway. In addition, we synthesized and
characterized 8e. A mixture of two dihydroxylated isomers (diols), 10a and 10b
was successfully resolved and characterized. A click reaction of 10b and 11
yielded 12. Improving the yield of the reaction and use of a better visualization
technique for 12 clearly need further development in the future.
Similar to compound 16, more HIGAs where the inositol core is coupled to
different non-carbohydrate moieties bearing maleimide or other fluorophore tags
need to be synthesized and evaluated. HIGAs with fluorophore tags should be
useful diagnostic tools for studying structure-activity relationship of IGs.
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CHAPTER 5
EXPERIMENTAL PROCEDURES
All anhydrous reactions were performed under argon/nitrogen
atmosphere. Reagents and solvents obtained from commercial sources were
used without purification with the following exceptions. Methanol was distilled
from magnesium metal and iodine crystals. Dimethyl sulfoxide was distilled from
barium oxide. Methylene chloride was distilled at its boiling point. Pyridine was
distilled from barium oxide or calcium hydride. TLC was performed on Baker
glass backed silica gel plates (0.25-mm thickness). TLC monitored reactions and
compounds were visualized by ultraviolet illumination and by using ethanolic
solution of 2.5% p-anisaldehyde for staining. Purification of compounds was
done by flash chromatography. In some cases preparative scale separations
were performed on preparative TLC plates. Solvents were removed in vacuum
on a Buchi rotary evaporator. NMR data were obtained on an Inova 400 MHz or
300 MHz spectrometer and the chemical shift is reported in parts per million (δ).
Tetramethylsilane was used as an internal standard for all proton NMR spectra.
High resolution mass spectroscopy (HRMS) data were obtained on a mass
spectrometer using electrospray as the ionization method.
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Methyl-D-xylopyranoside (2).58 Distilled methanol (40 mL) was added to a flask
containing D-xylose 1 (6 g, 40 mmol) and Dowex (2 g). The reaction mixture was
refluxed until the TLC (acetonitrile-water, 85:15) indicated completion of reaction,
approximately 20h. The resulting mixture was filtered over Celite, and the filtrate
was evaporated to constant weight, producing 6.18 g (94% yield) of mixture of
two isomers α and β methyl D-xylopyranoside 2. 1H NMR for mixture of 2α and
2β (400 MHz, D2O): δ 4.13 (dd, J = 7.6, 2.8 Hz, 1H), 3.81-3.75 (m, 1H), 3.54-3.47
(m, 2H), 3.45–3.38 (m, 4H), 3.32–3.29 (m, 1H), 3.27-3.20 (m, 6H), 3.18–3.09 (m,
2H), 3.08–3.02 (m, 1H).
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Methyl-2,3,4-Tri-O-benzyl-D-xylopyranoside (3).58 Dimethyl sulfoxide (56 mL,
510 mmol) was added to sodium hydride (6.66 g, 540 mmol) under continuous
stirring to produce the dimsyl carbanion. A solution of 2 (6.18 g, 120 mmol) in
dimethyl sulfoxide (19 mL, 173 mol) was added dropwise to the reaction mixture
over a period of 1h. A solution of benzyl bromide (21 mL, 550 mmol) in dimethyl
sulfoxide (17 mL, 156 mmol) was added dropwise to the reaction mixture over a
period of 3h and allowed to stir until completion of reaction, which was confirmed
by TLC (ethyl acetate-hexane, 30:70). The crude was diluted with ice-cold water
(200 mL), and the crude was extracted with diethyl ether (2 x 50 mL). The
combined organic layers were dried over MgSO4 and filtered. The solvent was
evaporated, and the residue was purified by flash chromatography (silica, 1:4
ethyl acetate-hexane) to give 7.77 g (48% yield) of 3 as yellow oil. 1H NMR for 3
(400 MHz, CDCl3): δ 7.36–7.24(m, 15H), 4.76–4.61 (m, 7H), 3.92 (m, 1H), 3.82–
3.74 (m, 3H), 3.54–3.50 (m, 1H), 3.43 (s, 3H).
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2,3,4-Tri-O-benzyl-D-xylopyranose (4).59 D-xylopyranoside, 3 (6 g, 6.9 mmol)
was dissolved in a mixture of 2 N sulfuric acid (17 mL), dioxane (18 mL, 102
mmol) and glacial acetic acid (19 mL). The reaction mixture was refluxed until
TLC (ethyl acetate-hexane, 30:70) showed completion of reaction (approximately
20h). The crude was filtered and crystallized from hexane-ether (1:1) to obtain
5.53 g (95% yield) of 4 as white crystals. 1H NMR for 4 (400 MHz, CDCl3): δ
7.35–7.24 (m, 30H), 5.17 (m, 1H), 5.10 (m, 1H), 4.74–4.50 (m, 12H), 4.08 (m,
1H), 3.89–3.75 (m, 6H), 3.70–3.60 (m, 4H), 3.03 (m, 1H).
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2(R),3(R),4(S)-Tribenzyloxy-5-hexene-1-ol (5). 60 To a suspension of methyltriphenylphosphonium bromide (24.65 g, 69 mmol) in dry tetrahydrofuran (THF)
(116 mL) added n-BuLi (55 mL, 65 mmol) was added dropwise at 0°C, and the
reaction mixture was stirred for 2h. A solution of 4 (10 g, 23.78 mmol) in THF (73
mL) was added to the red reaction mixture at 0°C, and the reaction mixture was
stirred overnight at room temperature and then at 45°C for 6h. Reaction mixture
was then cooled to -10°C and filtered. NH4Cl (100 mL of 1M aqueous solution)
was then added, and the suspension was extracted with ether (2 x 100 mL). The
combined organic layers were dried over MgSO4 (s) and filtered. Flash
chromatography (silica gel, ethyl acetate-hexane, 30:70) was done to purify 5
producing 5.43 g (55% yield). 1H NMR for 5 (400 MHz, CDCl3): δ 7.40 – 7.25 (m,
15H), 5.92 – 5.80 (ddd, 1H), 5.36 – 5.29 (m, 2H), 4.73 (s, 1H), 4.61 (d, 1H), 4.35
(d, 1H), 4.10 (m, 1H), 3.70 – 3.50 (m, 4H), 2.10 (br s, 1 H).
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2(S),3(R),4(S)–Tribenzyloxy-5-hexenal (6).61 Dimethyl sulfoxide (3.37 mL, 48
mmol) was added dropwise to a stirred solution of oxalyl chloride (2.03 mL, 24
mmol) in CH2Cl2 (40 mL) at -78°C. After 4 min, a solution of 5 (4.01 g, 9.6 mmol)
in CH2Cl2 (25 mL) was added to the reaction mixture over 10 min, and the
reaction mixture was stirred for 25 min at the same temperature. Triethylamine
(10.6 mL, 77 mmol) was added within 4 min, the reaction mixture was stirred for
additional 5 min and then warmed up to room temperature. Water was then
added to the reaction mixture. The aqueous layer was extracted with CH2Cl2 (2 x
20 mL). The organic layers were combined and washed with NH4Cl (2 x 30 mL,
1M aqueous solution), water (30 mL), brine (30 mL) and dried over MgSO4.
Crude 6 (3.99 g) was obtained after evaporation of the solvent. The material was
considered sufficiently pure and was used in the next reaction without
purification.
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3(S),4(R),5(R)-Tribenzyloxy-6-hydroxy-1,7-octadiene (7a and 7b). 62
A freshly prepared 2M solution of vinylmagnesium bromide in THF (64 mL) was
added to a flask containing dry CH2Cl2 (20 mL) at -78°C. To the resulting
solution, crude 6 (3.99 g, 9.5 mmol) in CH2Cl2 (0.27 mL) was added dropwise
during 30 min. The mixture was stirred at that temperature for 3h, and then the
reaction was quenched by addition of dry MeOH (10 mL). The mixture was
warmed to room temperature and washed with NH4Cl (80 mL, 1M aqueous
solution), water (80 mL), and brine (80 mL) and dried over MgSO4 to give 2.35 g
(55% yield over two steps) of mixture of 7a and 7b. 1H NMR spectrum of 7a and
7b was identical to that reported previously.62
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3(S),4(R),5(R)-Tribenzyloxy-(6R)-hydroxycyclohexene (8a and 8b).68
To a solution of 7a and 7b (1.16 g, 2.6 mmol) in CH2Cl2 (100 mL)
(Cy3P)2RuCl2(CHPh) (0.14 g, 0.16 mmol) was added at room temperature. The
reaction mixture was stirred for 30 min and opened to the atmosphere for 4h.
The solvent was evaporated, and the crude was purified by flash
chromatography (hexane: Et2O, 1:1) to give 0.49 g (45% yield) of 8a followed by
0.41 g (38% yield) of 8b. 1H NMR for 8a (400 MHz, CDCl3): δ 7.35-7.25(m,
15H), 5.77 (d, J = 2.32 Hz, 2H), 4.94-4.66 (m, 6H), 4.18 (m, 1H), 4.02 (d, J =
7.24 Hz, 1H), 3.90 (dd, J = 2.84, 7.10 Hz, 1H), 3.46 (dd, J = 4.12, 9.72 Hz, 1H),
2.19 (bs, 1H). 1H NMR for 8b (400 MHz, CDCl3): δ 7.35-7.25(m, 15H), 5.69 (m,
2H), 5.02 (d, J =11.3 Hz) 4.96-4.62 (m, 5H), 4.37-4.25 (m, 2H), 3.77 (dd, J
=10.3, 7.3 Hz, 1H), 3.52 (dd, J = 10, 7.6 Hz, 1H), 2.16 (d, J = 3.3 Hz, 1H).
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Tri-O-benzyl-6-azidocyclohexene (9).69,70 To a precooled (0°C) solution of 8b
(0.17 g, 0.40 mmol) in dichloroethane (3.4 mL), mesyl anhydride (0.076 g, 6.5
mmol) was added. Triethylamine (1.1 mL, 8.1 mmol) was added dropwise to the
reaction mixture. The reaction mixture was stirred at 0°C until TLC indicated
completion of reaction. The reaction mixture was diluted with ethyl acetate (60
mL) and washed with dilute acetic acid (2 x 6 mL) followed by a saturated
solution of sodium bicarbonate (6 mL) and then dried over MgSO4. The solvent
was evaporated, and the crude residue was dried by coevaporation with toluene.
The residue was placed in a flask to which sodium azide (0.13 g, 1.34 mmol) was
added followed by dimethyl formamide (1.9 mL). The reaction mixture was
stirred and heated at 85°C. On completion of the reaction, dimethyl formamide
was removed by coevaporation with toluene. The residue was diluted with ethyl
acetate, and the organic phase was washed with water (2 x 2 mL) and brine (2 x
2 mL), then dried over sodium sulfate. The solvent was evaporated, and the
residue was purified by flash chromatography (hexane: Et2O, 1:5) to give 0.072 g
(41% yield) of 9. 1H NMR for 9 (400 MHz, CDCl3): δ 7.35-7.25(m, 15H), 5.70 (d,
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J = 10.4 Hz, 1H), 5.47 (d, J = 10 Hz, 1H), 4.94-4.66 (m, 6H), 4.11 (m, 2H), 3.70
(dd, J = 8, 10.4 Hz, 1H), 3.55 (dd, J = 8.4, 10 Hz, 1H).
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Tri-O-benzyl-6-azido-deoxy-myo-inositol (10a and 10b).68 To a solution of 9
(8 mg, 0.018 mmol) in water: acetone (1:1, 0.73 mL) N-methyl morpholine Noxide (2.4 mg, 0.068 mmol) was added followed by osmium tetraoxide (42.24 µL
of 10 mg/mL of aqueous solution of osmium tetroxide). The reaction mixture was
stirred until the reaction was complete and monitored by TLC. Diethyl ether was
(4 mL) added to the reaction mixture, and the organic layer was washed with
10% aqueous sodium thiosulfate (3 mL) followed by water (3 mL) and dried over
MgSO4. The solvent was evaporated to give crude residue. Flash
chromatography (silica gel, Hexane: ether, 1:1) gave 1.5 mg of 10b followed by
0.5 mg of 10a (23% yield). 1H NMR for 10b (400 MHz, CDCl3): δ 7.35-7.25(m,
15H), 4.94-4.66 (m, 6H), 4.02 (d, J = 7.24 Hz), 3.90 (dd, J = 7.44 Hz, J = 7.44
Hz), 3.46 (dd, J = 4.12 Hz, J = 4.12 Hz), 2.69-2.49 (m, 1H).
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1-(Benzylthio)-2-propyne (11). 66 α-Toluene thiol A (5 g, 40.2 mmol) was
dissolved in degassed methanol (0.5 M, 80.5 mL) at 0°C, and solid KOH (2.7 g,
48.3 mmol) was added to the reaction mixture. After 5 minutes, propargyl
bromide B, 80% in toluene (6.5 mL) was added, and the reaction mixture was
warmed to room temperature. TLC indicated completion of reaction in 3h.
Methanol was removed from the reaction mixture under vacuum, and the residue
was diluted with water (25 mL). The residue was extracted with ethyl acetate (2
x 50 mL) and dried over MgSO4. The solvent was evaporated to give 11 (5.45 g,
83% yield) as yellow oil. The crude was then purified by flash chromatography.
1

H NMR for 11(400 MHz, CDCl3): δ 7.38 – 7. 27 (m, 5H), 3.88 (s, 2H), 3.08 (d,

2H, J=2.8 Hz), 2.31 (t, 1H, J=2.6 Hz).
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Tri-O-benzyl-6-(4-benzylthiomethyl)-1, 2, 3-triazole-deoxy-myo-inositol
(12).67 To a solution of 10b (5 mg, 0.0105 mmol) in THF (42 µL), propargyl
sulfide (0.002 mg, 0.019 mmol) was added at room temperature. The reaction
mixture was stirred, and copper sulfate pentahydrate (0.21 mg, 0.84 µmol)
followed by sodium ascorbate (0.41 mg, 2.07 µmol) were added to the reaction
mixture. The reaction mixture was stirred until TLC indicated complete
disappearance of starting material. Water (0.3 mL) was then added to the
reaction mixture, and the aqueous layer was washed with ethyl acetate (2 x 0.5
mL). The organic layer was washed with water (0.5 mL) and brine (0.5 mL) and
dried over MgSO4. The solvent was evaporated to give crude 12 (6.6 mg) as
white solid. 1H NMR for crude 12 (400 MHz, CDCl3): δ 7.55 (s, 1H), 7.29 – 7.
20 (m, 32H), 7.14 – 7.12 (m, 3H), 6.88 – 6.86 (m, 2H), 4.95 – 4.74 (m, 8H), 4.64
(d, 1H, J=11), 4.56 (d, 1H, J=10.8 Hz), 4.36 (d, 1H, J=10 Hz), 4.28 (s, 1H), 4.20
(m, 1H), 4.08 – 4.04 (m, 1H), 3.93 – 3.88 (m, 3H), 3.72 (d, 2H, J=9.2), 3.59 (d,
4H, J=4.8 Hz), 3.47 (s, 1H) 3.34 (d, 1H, J=10.8 Hz), 2.40 - 2.35 (m, 2H). HRMS
(ESI): m/z calculated for C37H39N3O5S: 638.2688. Found: 638.2684.
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6-[4-{5-(methylthio[acetylamino]-ethylamino)-napthalene-1-sulfonate}-1, 2,
3-triazole]-6-deoxy-myo-inositol-1,2-cyclic phosphate (16).67 MeOPOCl2 (500
µL) was added to pyridine (5 mL). The reaction mixture was stirred at room
temperature for 30 min. To a solution of 12 (6.6 mg, 0.0105 mmol, assuming
100% yield) in pyridine (70 µL), the above freshly prepared reagent (107 µL) was
added, and stirring was continued at room temperature until TLC (silica, 1:1:1
CHCl3-diethyl ether-MeOH) indicated completion of reaction. The reaction was
quenched by addition of NaHCO3 (0.2 mL), and the resulting mixture was coevaporated from heptane. The resulting crude was further co-evaporated with
toluene and then transferred to a flask containing THF (1.78 mL) under argon. In
a separate flask NH3 (5.35 mL) was condensed at -78°C and Na (14.28 mg) was
added. After 15 min when the blue color persisted, the crude dissolved in THF
was added dropwise, and the reaction mixture was stirred at -78°C for 15 min
and quenched with solid NH4Cl (32 mg) at -78°C. Methanol was added once the
blue color had disappeared, and the reaction mixture was warmed to 20°C. The
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solvent was evaporated to give the crude product. Tris HCl buffer (pH 7.5, 1 mL)
was added to the resulting crude under argon. The reaction mixture was allowed
to stir, and 1, 5-IAEDAN (4.56 mg, 0.0105 mmol) was added. The reaction
mixture was stirred for 2 h at room temperature to yield compound 16. HRMS
(ESI): m/z calculated for C23H26N5O11PS2 2- : 322.0443 Found: 322.0865.
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Phosphine Oxide (17).56 Chloromethylphosphonic dichloride (0.12 mL, 1.19
mmol) was dissolved in freshly distilled THF (2.4 mL). A solution of
phenylmagnesium bromide (1.0 M) in THF (2.4 mL) was added dropwise over 15
min. The resulting mixture was refluxed for 24h. The reaction was then
quenched by the addition of water (0.2 mL), and solvent was removed under
reduced pressure. The residue was taken up in CH2Cl2 and washed with water
(5 mL) and brine (5 mL). The organic layer was dried over anhydrous MgSO4(s)
and filtered, and solvent was removed under reduced pressure. The residue was
purified by flash chromatography (silica gel, 20% EtOAc in CH2Cl2). Phosphine
oxide 17 (0.12 g) was isolated as a white solid in 52% yield. 1H NMR spectrum
of 17 was identical to that reported previously.56
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Thiophosphine Oxide (18).56 Phosphine oxide 17 (40.6 mg, 0.16 mmol) was
dissolved in THF (0.96 L). Thioacetic acid (0.07 mL, 1.03 mmol) was added, and
the resulting solution was cooled in an ice bath. Argon (g) was bubbled through
the reaction mixture for 1h. Diisopropylethyl amine (0.177 mL, 1.07 mmol) was
added dropwise, and the resulting mixture was heated at reflux for 24h. Another
aliquot of thioacetic acid (0.07 mL, 1.05 mmol) was then added, followed by
triethyl amine (0.15 mL, 1.04 mmol). The reaction mixture was heated at reflux
for another 24h, after which solvent was removed under reduced pressure.
The resulting black oil was dissolved in CH2Cl2 (1 mL), and this solution was
washed with 2 N HCl (0.3 mL), saturated sodium bicarbonate solution (0.3 mL),
and brine (0.3 mL). The organic layer was dried over anhydrous MgSO4(s) and
filtered. Activated charcoal was added to this solution, which was then heated at
reflux for 30 min. The activated charcoal was removed by filtration, solvent was
removed under reduced pressure, and the residue was purified by flash
chromatography (silica gel, 70% ethyl acetate in hexane). Thioacetate 18 (22
mg, 48% yield) was isolated as orange oil. 1H NMR spectrum of 17 was identical
to that reported previously.56
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2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(9H-fluoren-9- ylmethoxy
carbonyl sulfanyl)-propionic acid; Fmoc-Cys (Fmoc)-OH (22).55 To a 0°C
solution of HCl-Cysteine-OH-H2O, A (351.7 mg, 2.0 mmol) in 20 mL of 50%
aqueous dioxane, fmocCl (1.1976 g, 4.6 mmol) was added, and adjusted to pH 7
by addition of 2 N NaOH. Continuous adjustment to pH 7 with 2 N NaOH was
done for 5h, at which point the reaction was concentrated in vacuo to remove
dioxane. Acidification to pH 2 with 1 N HCl was followed by extraction with
CH2Cl2 (3 x 100 mL). The organic layers were combined, dried over MgSO4,
filtered, concentrated in vacuo, and purified by flash column chromatography
(SiO2, 94/5/1) CH2Cl2/MeOH/AcOH, to give a white foam. The product was
recrystallized from EtOAc/hexanes to give 814.0 mg (72% yield) of product as a
white solid. 1H NMR spectrum of 22 was identical to that reported previously.55
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